The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies (Glutaminprojec)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Malnutrition occurs in up to 50% of patients requiring elective surgery for neoplastic diseases. It exerts a detrimental influence on outcome of surgery, because it can suppress immune function, exaggerate stress response and cause organ system dysfunction. Increased susceptibility to infection, protracted wound healing, impaired blood clotting and vessel wall fragility have been shown to be the leading causes of postoperative morbidity and mortality in malnourished patients undergoing major surgical resections.
This trial is designed as a prospective randomized, double-blinded, placebo-controlled pilot study in a academic single center in Switzerland. A total of 50 malnourished patients with gastro-intestinal tumors will receive orally glutamine or placebo-treatment during a period of 5 days prior to surgery. The investigators hypothesize that oral Glutamine administration is feasible, well tolerated, will decrease postoperative morbidity, will suppress postoperative cell damage and inflammatory response, and will improve the perioperative immunocompetence of the patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Malnourishment Gastrointestinal Tumors |
Dietary Supplement: Glutamine Drug: Placebo |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver) Primary Purpose: Supportive Care |
| Official Title: | The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies - A Randomized, Placebo-controlled Pilot Study |
- Morbidity [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
- Postoperative cell damage [ Time Frame: Up to seven days after surgery ] [ Designated as safety issue: No ]
- Inflammatory response [ Time Frame: Up to seven days after surgery ] [ Designated as safety issue: No ]
- Nutritional status [ Time Frame: Up to seven days after surgery ] [ Designated as safety issue: No ]
- Perioperative immunocompetence [ Time Frame: Seven and one day(s) before surgery. Postoperative week 1 and 6. ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 50 |
| Study Start Date: | May 2012 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Glutamin |
Dietary Supplement: Glutamine
30g oral glutamine / day for 5 days before surgery. Glutamine is an important nonessential amino acid and its intracellular concentration is much higher than that of other amino acids. Glutamine is released in large quantities from skeletal muscle and serves as an important carrier and donor of nitrogen
|
| Placebo Comparator: Placebo |
Drug: Placebo
30g oral maltodextrin / day for 5 days before surgery
|
Detailed Description:
Background
Malnutrition occurs in up to 50% of patients requiring elective surgery for neoplastic diseases. It exerts a detrimental influence on outcome of surgery, because it can suppress immune function, exaggerate stress response and cause organ system dysfunction. Increased susceptibility to infection, protracted wound healing, impaired blood clotting and vessel wall fragility have been shown to be the leading causes of postoperative morbidity and mortality in malnourished patients undergoing major surgical resections.
Immuno- or pharmaconutrition, defined as enteral or parenteral nutritional therapy based on a variety of products, such as omega-3-fatty acids, glutamine, arginine, sulfur-containing amino acids, nucleotides and anti-oxidants, is thought to have beneficial effects on postoperative recovery in a wide variety of surgical patients. Studies have shown its clinical effectiveness in terms of reduced postoperative complications, shortening the hospital stay and reduced hospitalization costs. Torosian et al. showed that severely malnourished patients benefit from preoperative nutrition, which reduce postoperative complications by 20%.
Although there is clinical evidence for the administration of immunonutrition to patients in the perioperative period, our understanding of the optimal type and time of immunonutrition, the characteristics of patients that benefit most, as well as the immunological mechanisms responsible for its beneficial effect is limited.
Objective
To assess in malnourished cancer patients the effect of 30g oral glutamine/day (3 sachets KABI® glutamine, Fresenius Kabi/day) for a preoperative course of 5 days on:
- Postoperative morbidity (surgical site infections, pneumonia, sepsis, incidence of wound and fascial dehiscence, incisional hernia, anastomotic break down)
- Nutritional status of the patients
- Postoperative cell damage and inflammatory response
- Perioperative immunocompetence
Methods
Seven days before surgery, the patients will receive a tetanus booster shot and will be randomly enrolled in either the 'glutamine group' or into the 'placebo group'. The patients as well as the responsible surgeons will be blinded.
- Patients in the 'glutamine group' will receive 30g oral glutamine / day for 5 days before surgery.
- Patients in the 'control group' will receive 30g oral maltodextrin / day for 5 days before surgery.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed and surgically resectable carcinomas
- Candidates for elective surgery with an estimated surgical stress score
- A Nutritional Risk Screening 2002 (NRS-200232) score ≥3
- Age ≥ 18 years
- Completed primary immunization with tetanus toxoid
- Last tetanus booster ≥10 years back
- Informed consent
Exclusion Criteria
- Refusal to participate
- Clinically relevant alterations of the pulmonary renal of hepatic function
- Insulin-dependent diabetes mellitus
- Pre-existing autoimmune diseases and immune-deficiencies
- Neutropenia
- Pregnancy
- Age <18 years
- Last tetanus booster <10 years back
- Ongoing infection
- Intestinal obstruction at the time of entry into the study
Contacts and Locations| Contact: Beat Schnueriger, MD | +41 31 632 24 03 | beat.schnueriger@insel.ch |
| Contact: Barbara Uhlmann | +41 31 632 23 26 | barbara.uhlmann@insel.ch |
| Switzerland | |
| Department of visceral surgery and transplant surgery, Berne University Hospital | Recruiting |
| Berne, Switzerland, 3010 | |
| Contact: Barbara Uhlmann, Study Nurse +41 31 632 23 26 barbara.uhlmann@insel.ch | |
| Principal Investigator: Beat Schnüriger, Dr. med. | |
| Principal Investigator: | Beat Schnüriger, Dr. med. | Department of visceral surgery and transplant surgery, Berne University Hospital |
More Information
No publications provided
| Responsible Party: | Dr. med. Beat Schnüriger, Insel University Hospital Berne |
| ClinicalTrials.gov Identifier: | NCT01552291 History of Changes |
| Other Study ID Numbers: | 170/11 |
| Study First Received: | March 5, 2012 |
| Last Updated: | December 27, 2012 |
| Health Authority: | Switzerland: Ethikkommission |
Keywords provided by University Hospital Inselspital, Berne:
|
Malnourishment Gastrointestinal tumors Immunocompetence |
Additional relevant MeSH terms:
|
Digestive System Neoplasms Gastrointestinal Neoplasms Malnutrition Neoplasms by Site |
Neoplasms Digestive System Diseases Gastrointestinal Diseases Nutrition Disorders |
ClinicalTrials.gov processed this record on May 22, 2013